Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2015

Open Access 01-12-2015 | Research

Immune microenvironment as a factor of breast cancer progression

Authors: Anatolii Romaniuk, Mykola Lуndіn

Published in: Diagnostic Pathology | Issue 1/2015

Login to get access

Abstract

Background

The rate of progression of the disease depends on various factors and the tumor microenvironment takes not the last place among them. One part of researchers argues that the presence of tumor-infiltrating leukocytes serves as a favorable marker of the disease. There exists a completely different point of view on the matter.
The investigation of the effects of the inflammatory infiltration on the course of breast cancer process.

Methods

We found a pronounced inflammatory infiltration in the tumor microenvironment in 24 cases. Nineteen cases of IDC without inflammatory infiltration were used as a control group. Immunohistochemical reaction showed expression of ERα, PR, HER2/neu, E-cadherin, Hsp90α, Bcl-2, CD3, CD79α, S100 and Myeloperoxidase receptors. Mathematical calculations were done using Microsoft Excel 2010 with 12.0.5 Attestat option.

Results

We have determined five variants of immune microenvironment: interstitial, trabecular, nodular, diffuse and mixed. We have established a direct correlation between the expression of ERα and PR and indirect correlation between the receptors of steroid hormones and HER2/neo in both groups of breast cancer. HER2/neo positive tumors in 100% of cases were accompanied by the presence of heat shock proteins. There was a combination of Bcl-2 presence with the steroid receptors expression in 90 % of cases. There was found the indirect correlation between the presence of B lymphocytes and expression of steroid receptors.

Conclusions

The presence of B lymphocytes in an inflammatory infiltrate leads to the disappearance of estrogen receptors and progesterone receptors. It provokes the accumulation of Hsp90 in a cell. It contributes to the stabilization of HER2/neu receptors and most proteins that promote tumor progression.

Virtual slides

Literature
1.
2.
Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, et al. International union of pharmacology. LXIV. Estrogen receptors. Pharmacol Rev. 2006;58(4):773–81.PubMedCrossRef
3.
Zagouri F, Sergentanis TN, Nonni A, Papadimitriou CA, Michalopoulos NV, Domeyer P, et al. Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions. BMC Cancer. 2010;10:353–60.PubMedCentralPubMedCrossRef
4.
Gadkar-Sable S, Shah C, Rosario G, Sachdeva G, Puri C. Progesterone receptors: various forms and functions in reproductive tissues. Front Biosci. 2005;10:2118–30.PubMedCrossRef
5.
Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: Pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;25(23):3525–33.
6.
Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer. 2011;104(1):120–7.PubMedCentralPubMedCrossRef
7.
Mohammed ZM, Going JJ, Edwards J, Elsberger B, Doughty JC, McMillan DC. The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2012;107(5):864–73.PubMedCentralPubMedCrossRef
8.
Domschke C, Schuetz F, Ge Y, Seibel T, Falk C, Brors B, et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res. 2009;69(21):8420–8.PubMedCrossRef
9.
Keibel A, Singh V, Sharma MC. Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Des. 2009;15(17):1949–55.PubMedCrossRef
10.
Schmidt C. Immune system’s Toll-like receptors have good opportunity for cancer treatment. J Nat Cancer Inst. 2006;98:574–5.PubMedCrossRef
11.
Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2011;109(8):2796–801.PubMedCentralPubMedCrossRef
12.
Sas L, Lardon F, Vermeulen PB, Hauspy J, Dam PV, Pauwels P, et al. The interaction between ER and NF-κB in resistance to endocrine therapy. Breast Cancer Res. 2012;14:212–20.PubMedCentralPubMedCrossRef
13.
Belguise K, Sonenshein GE. PKCθ promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor α synthesis. J Clin Invest. 2007;117:4009–21.PubMedCentralPubMed
14.
Reijm EA, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Gelder ME, et al. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat. 2011;125:387–94.PubMedCrossRef
15.
Wang X, Belguise K, O’Neill CF, Sánchez-Morgan N, Romagnoli M, Eddy SF, et al. RelB NF-κB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Mol Cell Biol. 2009;29:3832–4.PubMedCentralPubMedCrossRef
16.
Orange JS, Levy O, Geha RS. Human disease resulting from gene mutations that interfere with appropriate nuclear factor-kappaB activation. Immunol Rev. 2005;203:21–37.PubMedCrossRef
17.
Werner AB, de Vries E, Tait SW, Bontjer I, Borst J. Bcl-2 family member Bfl-1/A1 sequesters truncated bid to inhibit is collaboration with pro-apoptotic Bak or Bax. J Biol Chem. 2002;277(25):22781–8.PubMedCrossRef
18.
19.
20.
Berezowska S, Novotny A, Bauer K, Feuchtinger A, Slotta-Huspenina J, Becker K, et al. Association between HSP90 and Her2 in Gastric and Gastroesophageal Carcinomas. PLoS One. 2013;8(7):37–45.CrossRef
21.
Lang SA, Klein D, Moser C, Gaumann A, Glockzin G. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther. 2007;6:1123–32.PubMedCrossRef
22.
Koga P, Xu W, Karpova TS. Hsp90 inhibition transiently activates Sic kinase ami promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci U S A. 2006;103(30):11318–22.PubMedCentralPubMedCrossRef
23.
Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol. 2004;6(6):507–14.PubMedCrossRef
24.
Kregel KC. Ileal shock proteins: modifying factors in physiological stress responses and acquired Ihemiotolerance. J Appl Physiol. 2002;92(5):2177–86.PubMedCrossRef
25.
Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. 2004;206:149–57.PubMedCrossRef
26.
Grad I, Picard D. The glucocorticoid responses are shaped by molecular chaperones. Mol Cell Endocrin. 2007;275(1–2):2–12.CrossRef
27.
Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer. 2010;103:668–75.PubMedCentralPubMedCrossRef
28.
Vaillant F, Merino D, Lee L, Breslin K, Pall B, Ritchie ME, et al. Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer. Cancer Cell. 2013;24(1):120–9.PubMedCrossRef
29.
Lindeman GJ, Visvader JE. Targeting BCL-2 in breast cancer: exploiting a tumor lifeline to deliver a mortal blow? Breast Cancer Manage. 2013;2:1–4.CrossRef
30.
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.PubMedCrossRef
31.
Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene. 2000;19(56):6627–31.PubMedCrossRef
Metadata
Title
Immune microenvironment as a factor of breast cancer progression
Authors
Anatolii Romaniuk
Mykola Lуndіn
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2015
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-015-0316-y

Other articles of this Issue 1/2015

Diagnostic Pathology 1/2015 Go to the issue

Research

Mitochondrial A12308G alteration in tRNALeu(CUN) in colorectal cancer samples

Research

Expression of HNF-1β in cervical carcinomas: an immunohistochemical study of 155 cases

Research

Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infection

Research

Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy

Research

Investigation of ossification in the posterior longitudinal ligament using micro-focus X-ray CT scanning and histological examination

Retraction Note

Retraction Note: Clinical application of contrast enhanced ultrasound to diagnose benign prostatic hyperplasia